Tricuspid Nonbacterial Thrombotic Endocarditis in Antiphospholipid Syndrome with Chronic Thromboembolic Pulmonary Hypertension: A Case Report

Clicks: 7
ID: 334142
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #381 of 408 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 408 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Antiphospholipid syndrome (APS) can cause both pulmonary vascular and valvular complications, but the coexistence of chronic thromboembolic pulmonary hypertension (CTEPH) with right-sided nonbacterial thrombotic endocarditis (NBTE) is rare. This case illustrates the interaction between immune-mediated thrombosis, persistent pulmonary vascular obstruction, and acute valvular involvement. Case Presentation A 54-year-old man with longstanding, refractory CTEPH and recurrent hemoptysis underwent multiple balloon pulmonary angioplasty procedures and escalation to advanced pulmonary hypertension therapy. Following the switch from warfarin to apixaban, surveillance echocardiography revealed thickening of the tricuspid leaflet tips with an attached thrombotic mass. In the presence of negative blood cultures, these findings raised suspicion for NBTE. Rheumatologic evaluation confirmed triple-positive APS. Warfarin was reinstated, and immunosuppressive therapy with corticosteroids, hydroxychloroquine, and plasmapheresis was initiated, resulting in complete resolution of the vegetations and clinical stabilization over one year. Discussion APS should be considered in patients with early-onset or treatment-refractory CTEPH. New sterile valvular vegetations warrant immediate autoimmune evaluation. In high-risk APS, vitamin K antagonists remain the preferred anticoagulant, and combined anticoagulation and immunosuppression can achieve full valvular recovery.
Reference Key
openalex_W7223674487 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shabnam Boudagh, Parnian Mansouri, Haniyeh Faraji Azad, Nazanin Hosseini, Amirreza Mosayebzadeh
Are you one of these authors? Claim your profile
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag770
URL
https://doi.org/10.1093/ehjcr/ytag770
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.